Recent proposals to revive inactive medicine licences in the UK are a welcome sign that policymakers are recognising a growing problem: medicines that should be available to patients, are quietly disappearing from the market.
That acknowledgement matters.
But there is a risk of misunderstanding what inactive licences actually represent - and therefore a risk of fixing the symptom rather than the cause.
Reviving inactive licences is not primarily about bringing manufacturing back to the UK. In many cases, the products concerned are manufactured overseas and always have been. What licence inactivity really reflects is a decision to pause or exit participation in the UK market.
And unless we understand why those decisions are being made, more and more medicines will fall into this category.
The Misunderstood Signal: Inactive Licences Are Not Administrative Drift
Inactive licences are often treated as technical artefacts - paperwork that has lapsed, products that could be restarted with the right nudge.
In reality, licence inactivity is usually the end point of a long economic process. Manufacturers do not stop supplying medicines casually. They do so when the cost, complexity, and risk of serving the UK market outweigh the returns - even when patient demand remains steady.
That distinction is crucial. Because if a medicine is clinically necessary but economically unsustainable, reactivating its licence does not make it viable. It simply delays the next withdrawal.
Price Erosion Is Not Efficiency - It’s a Withdrawal Signal
Generic price erosion is still widely framed as evidence that competition is working. Falling prices are assumed to mean efficiency, value for money, and a healthy market.
That assumption no longer holds.
When medicines are sold into the UK market at prices measured in pennies, price stops being a proxy for efficiency and becomes a proxy for fragility.
Manufacturers are routinely competing on differences of one or two pence per pack while absorbing:
-
rising API and excipient costs
-
higher energy and transport prices
-
increasing regulatory and compliance burdens
-
fixed quality and release costs that do not flex with reimbursement
At that point, maintaining a product becomes an act of subsidy rather than strategy.
Licences are kept alive only as long as losses can be absorbed elsewhere.
When they can’t, licences lapse.
Supplying the UK Market: High Standards, Thin Margins
Whether medicines are manufactured domestically or overseas, supplying the UK market comes with a distinctive economic profile.
The UK combines:
-
extremely low reimbursement prices
-
high regulatory and quality expectations
-
limited tolerance for price movement
-
and slow mechanisms for recognising economic stress
For UK-based manufacturers, this is particularly acute because fixed costs are higher - but the issue is not limited to domestic production. Imported products face the same pricing pressure, the same reimbursement constraints, and the same exposure to loss.
The market treats all packs as economically interchangeable, regardless of how much resilience, compliance,or responsiveness is built into the supply chain.
The predictable outcome is that manufacturers reduce exposure, prioritise other markets, or quietly mothball products rather than formally withdrawing them.
Licence inactivity is not a failure of capability. It is a rational response to market design.
The Repeatable Failure Pattern Behind Shortages
Across product after product, the same sequence plays out:
-
Sustained price compression pushes margins below viable levels
-
Manufacturers quietly reduce output or deprioritise the UK
-
Market depth erodes, even though headline availability appears stable
-
A minor disruption occurs - an API delay, audit issue, or logistics shock
-
Supply collapses rapidly
-
Emergency imports, concessions, and political concern follow
By the time official shortage mechanisms activate, the underlying capacity has already gone.
Licence inactivity is not the starting point in this sequence. It is the outcome.
Why Reviving Licences Alone Won’t Stop the Pipeline
Initiatives to revive inactive licences may bring short-term relief for individual products.
They may even succeed in reintroducing supply in a handful of cases.
But unless the economics of supplying the UK market change, today’s active licences are tomorrow’s inactive ones.
Reactivation addresses availability after viability has already failed. It does nothing to alter the incentives that caused manufacturers to step back in the first place.
Without changes to how early economic warning signals are recognised - prolonged ultra-low pricing, shrinking manufacturer participation, declining market depth - the pool of inactive licences will continue to grow.
Stability Is Cheaper Than Crisis
Emergency imports, unlicensed supply, regulatory workarounds, and clinical substitutions are expensive - financially and operationally. They are also largely avoidable.
The data already shows where fragility is building, often months before shortages are formally declared. Ignoring those signals does not make shortages unpredictable. It guarantees they will repeat.
Reviving inactive licences may help treat the immediate shortage. But unless we address the root cause - the economics of supplying the UK medicines market - we will continue to create the very conditions that make licences inactive in the first place.
Until that is confronted, shortages will remain a structural feature of the system, not an exception.
The Real Root Cause We Keep Avoiding
If we are serious about preventing medicines from becoming economically inactive, we need to be honest about what is driving this behaviour in the first place.
The root cause is not licensing process.
It is not manufacturing location.
And it is not a lack of goodwill from industry.
It is the systematic driving down of generic medicine prices to the penny, combined with a failure to fix:
-
the community pharmacy contractual framework, and
-
the pricing and reimbursement policy for medicines supplied in primary care.
These policies are tightly linked - and together they create a market where medicines are expected to remain continuously available, even when the economics make that expectation irrational.
Generic medicines are pushed to ultra-low prices through reimbursement and tariff mechanisms that assume infinite resilience in the supply chain. Community pharmacies, operating under a contract that does not adequately reflect their role or risk, are left absorbing volatility at the front line. Manufacturers, meanwhile, are expected to continue supplying products that are no longer commercially viable, with price concessions and emergency measures used as retrospective sticking plasters rather than structural fixes.
In that environment, licence inactivity is not a surprise.
It is an inevitability.
Reviving inactive licences may help recover individual products after failure has already occurred. But unless the underlying pricing and reimbursement framework changes, the system will continue to manufacture fragility — pushing more medicines into loss-making territory, and more licences into inactivity.
This is not a failure of execution.
It is a failure of market design.
Until generic pricing, pharmacy remuneration, and primary care reimbursement policy are aligned around sustainability rather than lowest possible cost, the UK will remain trapped in a cycle of erosion, exit, and crisis management.
Inactive licences are not the problem we need to solve.
They are the signal telling us - clearly and repeatedly - that the system is broken.